Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback